title: Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
abstract: Cholinesterase inhibitor (ChEI) medications (ie, donepezil, rivastigmine, and galantamine) have been useful in slowing the progression of the mild to moderate stages of Alzheimer's disease (AD). Findings supporting this have largely relied on a global error score from the Alzheimer's Disease Assessment Scale and have not described the nature of the memory problems. We examined this issue by comparing learning, recall, and recognition scores among 2 groups of mild to moderately demented AD patients. Participants were patients from a memory clinic who either were on ChEI treatment (AD+ChEI, n = 14) or had never taken a ChEI (AD-ChEI, n = 14). Participants underwent a comprehensive neuropsychological evaluation, including administration of the CERAD Word List Memory test. Results indicated no significant group difference for learning and delayed free recall, but the AD+ChEI group had significantly fewer errors than the AD-ChEI group on the CERAD Recognition test. Our findings provide preliminary evidence that the aspect of memory that is most affected by ChEIs appears to be facilitation of retention of new information in memory. The implications of this on clinical care and functional abilities as well as future directions are discussed.
authors.affiliation: Roskamp Institute Memory Clinic, Tampa, Florida 33617, USA. TACrowell@excite.com
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Crowell
authors.forename: Juno
authors.initials: J
authors.lastname: Paramadevan
authors.forename: Laila
authors.initials: L
authors.lastname: Abdullah
authors.forename: Michael
authors.initials: M
authors.lastname: Mullan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008569:Memory Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011939:Mental Recall / Q000187:drug effects*; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D048448:Phenylcarbamates / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D012153:Retention, Psychology / Q000187:drug effects*; D000068836:Rivastigmine; D014706:Verbal Learning / Q000187:drug effects*
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D000068836:Rivastigmine